---
type: tissue
aliases: [venous system, venous wall, vein, veins, venules, great saphenous vein, GSV, small saphenous vein, capacitance vessels]
parent-system: cardiovascular-system
key-cell-types: ["[[endothelial-cells]]", "[[vsmc]]"]
key-aging-phenotypes: ["[[chronic-venous-disease]]"]
related-hallmarks: ["[[altered-intercellular-communication]]", "[[chronic-inflammation]]", "[[cellular-senescence]]"]
verified: true
verified-date: 2026-05-25
verified-by: claude
verified-scope: "Structural/aging sections verified against Eberhardt 2014 (Circulation, full PDF), Raffetto 2021 (Vessel Plus, full PDF), Maurins 2008 (J Vasc Surg, full PDF); Lim 2011 IVC-stretch data cross-checked via PMC full text; Bergan 2006 verified against PubMed metadata. Deep venous-valve sections (microanatomy/development, failure mechanisms, cardiac-valve comparison, genetic bridge) verified 2026-05-25 against full PDFs: Fukaya 2018 (Circulation, local PDF), Sabine 2012 (Dev Cell, local PDF), Welsh 2019 (JCI, local PDF), Lyons 2021 (JCI Insight, local PDF), Mellor 2007 (Circulation, local PDF). Key corrections applied: (1) FBN2 corrected from GWAS locus to eQTL gene; (2) perivalvular endothelial program corrected from anticoagulant to antithrombotic; (3) Munger 2013 + Sabine 2012 footnotes clarified as lymphatic-valve primary evidence extrapolated to venous valves; (4) Welsh 2019 journal issue corrected to 129(12). Banjo 1987, Phillips 2004, Bovill 2011, Mackman 2012, Bazigou 2009, Murtomaki 2014, Lange 2006, Saxon 2017, Raffettophleb 2008, Berganjvs 2008, Takase 2004, ChenMMP 2017, Ahalya 2025, Absi 2018, Rajamannan 2003, Garg 2005, Kuhne 2013, Ho 2023 not re-read from full PDF (status: not_oa or not yet downloaded); cross-checked against PMC abstracts only — recommend full-PDF re-check on next lint pass for these. Canonical-DB identity fields (ICD, anatomy ontology) not independently re-checked."
---

# Veins (venous system)

The **venous system** is the low-pressure, high-compliance return circulation. Veins are **capacitance vessels** — at rest they hold roughly two-thirds of total blood volume — and are structurally distinct from [[arteries]]: thinner walls, a much smaller tunica media with less [[eln|elastin]] and smooth muscle relative to lumen, greater distensibility, and — critically — **bicuspid venous valves** that enforce unidirectional flow against gravity. This page is the venous counterpart to [[arteries]]; the aging *disease* of this tissue is [[chronic-venous-disease]] (varicose veins / CVI).

## Wall structure

Like arteries, veins have three layers, but the proportions differ sharply:

| Layer | Vein | Contrast with artery |
|---|---|---|
| **Tunica intima** | Endothelium + thin subendothelial layer; folds form the **valve cusps** | Similar endothelium; valves are venous-specific |
| **Tunica media** | Thin; sparse [[vsmc|smooth muscle]] + collagen, relatively little elastin | Much thicker + elastin-rich in arteries (esp. elastic arteries) |
| **Tunica adventitia** | Often the **thickest** layer; collagen (types I and III), some longitudinal smooth muscle | Relatively thinner in arteries |

The relatively elastin-poor, collagen-dominated, thin-media wall makes veins compliant capacitance reservoirs but also means wall integrity depends heavily on **ECM balance** — which is where venous aging strikes (below).[^bergan][^eberhardt]

## Venous valves and the calf muscle pump

Lower-limb venous return against gravity depends on two coupled systems:

1. **Bicuspid venous valves** — more numerous distally in the leg, they prevent retrograde (refluxing) flow. Valve competence is the single most important determinant of ambulatory venous pressure.
2. **The calf muscle pump** ([[skeletal-muscle]]) — contraction of the calf during walking compresses the deep veins and propels blood upward; combined with competent valves, this drops foot venous pressure from the standing hydrostatic column (~90 mmHg) toward ~30 mmHg during ambulation.

Failure of either — valve incompetence or an inadequate pump — raises **ambulatory venous pressure**, the hemodynamic driver of [[chronic-venous-disease]].[^bergan][^eberhardt]

## Aging of the venous wall

Venous aging is the low-pressure, valve-centric analogue of [[arterial-stiffening]]:

- **ECM remodeling / MMP imbalance.** Elevated venous hydrostatic pressure, hypoxia, and inflammation upregulate **matrix metalloproteinases** ([[mmp-1]], [[mmp-2]], [[mmp-3]], MMP-7; MMP-9 enriched in endothelial cells and medial VSMCs) that degrade **collagen and [[eln|elastin]]**, shifting the balance with their inhibitors ([[timp-1]]) toward net proteolysis. This weakens the wall (→ dilation) and, via BKCa-channel-mediated smooth-muscle hyperpolarization (blocked by iberiotoxin), promotes [[vsmc|smooth-muscle]] relaxation/dilation directly.[^raffetto2021][^raffetto2008]
- **Valve degeneration.** Valves become incompetent with age, especially in the **superficial** system; population data show superficial-vein reflux rising markedly with age while deep-system reflux does not.[^maurins]
- **Endothelial dysfunction + inflammation.** Venous hypertension drives leukocyte–endothelial adhesion and glycocalyx disruption, a [[chronic-inflammation|chronic inflammatory]] wall state, with plausible contribution from [[endothelial-cells|endothelial]]/fibroblast [[cellular-senescence]] and [[sasp]]-associated ECM turnover ([[altered-intercellular-communication]]).[^bergan][^eberhardt]
- **Stretch/hypoxia mechanotransduction.** Sustained wall stretch upregulates HIFs and reduces contractility, linking distension to a pro-remodeling hypoxic state.[^lim2011]

## Venous valve microanatomy and development

Venous valves are **bicuspid "pocket" (parietal) valves**: two endothelium-covered leaflets seated in a slightly dilated segment of wall, the **valve sinus**, with a thickened wall ridge (the **agger**) at the leaflet attachment. They occur down to tributaries as small as ~0.1 mm.[^phillips2004] Their distribution is **distal-predominant and proximally sparse**: the inferior vena cava is **valveless in essentially all individuals**, the common iliac carries valves in only ~1–7% and the external iliac ~22–33%, rising to ~67–93% near the saphenofemoral junction and becoming dense in the calf and distal veins.[^banjo1987] This gradient matters — the proximal valveless segments place the entire orthostatic pressure column on the first competent valve downstream.

The **valve sinus pocket is a low-shear, hypoxic microenvironment** behind the leaflet. This is functionally double-edged: it is where the leaflet's anticoagulant endothelial program is most needed, and it is the **anatomical nidus where deep-vein thrombi initiate** (valvular stasis + local hypoxia drive thrombosis).[^bovill2011][^mackman2012]

**Valve endothelial specialization + the developmental program.** The endothelium lining the valve is not generic luminal endothelium: hemodynamic forces (oscillatory/low shear in the sinus) induce a **distinct, antithrombotic perivalvular endothelial gene program** (high THBD/thrombomodulin, EPCR, and TFPI; low vWF), and disrupting it promotes DVT.[^welsh2019] Valve morphogenesis runs on a program **shared with lymphatic valves**: mechano-sensing activates the transcription factors **PROX1 and FOXC2**, which cooperate to control **connexin-37 (GJA4)** and **calcineurin/NFATc1** signaling.[^sabine2012] In Cx37-null mice, lymphatic valves are absent and the few mature venous valves that do form are severely reduced;[^munger2013] integrin-α9/fibronectin-EIIIA matrix assembly[^bazigou2009] and Notch[^murtomaki2014] are also required. Crucially, this program **overlaps with cardiac valve development** — NFATc1,[^lange2006] BMP2,[^saxon2017] Notch, Wnt, periostin, and **endothelial-to-mesenchymal transition (EndMT)** are shared between the two valve beds. The leaflet's internal ECM stratification (dual endothelial layers over a collagen–elastin core with a proteoglycan-rich middle) is well-documented for cardiac valves but largely **extrapolated** to venous valves rather than directly characterized. #gap/no-mechanism

## Venous valve failure — cellular mechanisms

Incompetence arises by two distinct routes that the literature is careful to separate:[^raffettophleb2008][^berganjvs2008]

1. **Primary valvular incompetence** — the leaflet itself stretches, elongates, thins, or (rarely) is congenitally absent; commissures widen. Human **EPHB4 loss-of-function causes venous valve aplasia/agenesis**,[^lyons2021] and **FOXC2 mutations** (lymphedema-distichiasis syndrome) cause primary lower-limb venous valve failure[^mellor2007] — direct genetic proof that the developmental program governs adult valve competence.
2. **Annular (wall) dilation** — the vein wall dilates at the valve station until the two cusps can no longer **coapt**, producing reflux through structurally intact leaflets. This couples valve failure directly to the [vein-wall ECM/MMP remodeling above](#aging-of-the-venous-wall).
3. **Secondary (post-thrombotic) destruction** — a prior DVT scars and tethers the leaflets; this is the most damaging form and the reason prior DVT is the strongest progression risk factor.

Across all three, the **valve sinus inflammatory cascade** is central: the low-shear pocket traps leukocytes; experimental venous hypertension drives **monocyte/macrophage infiltration of the leaflets** with progressive remodeling,[^takase2004] and **MMP-mediated leaflet ECM degradation**[^chenmmp2017] weakens the cusp. There is growing evidence that **EndMT is reactivated in varicose veins** under altered flow[^ahalya2025] — a striking echo of the EndMT that built the valve in development and that drives cardiac valve disease. **Whether venous valve *number* declines with chronological age is widely repeated but not cleanly established** in the primary literature. #gap/unsourced

## Comparison to cardiac (heart) valves

The two valve systems share a developmental origin and several failure mechanisms, but diverge sharply in structure and dominant pathology:

| Feature | Venous valve | Cardiac valve ([[heart]]) |
|---|---|---|
| Geometry | Bicuspid pocket valve in a sinus | Semilunar (aortic/pulmonary, 3 cusps) or atrioventricular (mitral 2 / tricuspid 3) |
| Pressure load | Low (gravity/hydrostatic column) | High (systemic/pulmonary arterial pressure) |
| Leaflet cell populations | Specialized valve endothelium; a resident interstitial-cell population is **not** well characterized #gap/no-mechanism | Valve endothelial cells (VECs) **+ a defined valve interstitial cell (VIC) population** |
| ECM organization | Collagen–elastin core + proteoglycan (largely extrapolated) | Trilaminar: **fibrosa** (collagen) / **spongiosa** (proteoglycan) / **ventricularis-atrialis** (elastin) |
| Shared development | PROX1, FOXC2, NFATc1/calcineurin, connexins, EndMT | NFATc1, Notch1, BMP, Wnt, periostin, EndMT |
| Dominant aging failure | Reflux (leaflet stretch + wall dilation) ± post-thrombotic scarring | **Calcific stenosis** (osteogenic VIC) or **myxomatous prolapse** (proteoglycan accumulation) |
| Calcification | Not a feature | Prominent (esp. aortic) |

**What's shared:** MMP/ADAMTS-driven ECM degradation, proteoglycan/versican remodeling, mechanical-stress-driven cell activation, and EndMT reactivation appear in both. Myxomatous mitral valve degeneration (mitral valve prolapse) is driven by proteoglycan accumulation, VIC activation, and ADAMTS5/versican turnover[^absi2018] — conceptually parallel to venous-wall ECM proteolysis. **What differs:** osteogenic **calcification** (VIC → osteoblast transdifferentiation via RUNX2/BMP, repressed by NOTCH1)[^rajamannan2003][^garg2005] and a **defined VIC population** are hallmarks of cardiac valves with no clear venous analogue.

**The genetic bridge.** This is the most striking correlation: the varicose-veins GWAS identifies 30 independent loci, several of which implicate machinery central to *cardiac* valve and connective-tissue biology — **PPP3R1** (calcineurin B regulatory subunit, i.e. the NFATc1/calcineurin valve-development axis), **PIEZO1** (a mechanosensor near the 16q24 locus), and **CASZ1** (strongest association; a cardiac-development/blood-pressure locus on chr1) are confirmed GWAS hits. **FBN2** (fibrillin-2, the Marfan-spectrum connective-tissue machinery) appears in eQTL analysis of the PIEZO1-region lead SNP rs2911463 as a regulated downstream gene — it is an eQTL association, not itself an independent GWAS locus.[^fukayaval] Connective-tissue disorders hit both beds — **FBN1** (fibrillin-1) mutations in Marfan predict mitral valve prolapse,[^kuhne2013] while **FOXC2** governs venous valves. And remarkably, **PROX1 — the canonical venous/lymphatic valve transcription factor — also protects against myxomatous heart-valve degeneration** by restraining PDGF-B,[^ho2023] a direct molecular thread tying the two valve systems together. A *clinical co-occurrence* of varicose veins and mitral valve prolapse is mechanistically plausible from this shared connective-tissue/calcineurin biology but is **not cleanly established epidemiologically**. #gap/needs-replication

For the engineering counterpart — can these valves be repaired or replaced? — see [[../interventions/procedural/venous-valve-reconstruction]].

## Clinically important veins (lower limb)

- **Superficial system:** great saphenous vein (GSV) and small saphenous vein (SSV) — the usual site of truncal reflux and the targets of endovenous ablation in [[chronic-venous-disease]].
- **Deep system:** femoral, popliteal, tibial veins — deep reflux is more often post-thrombotic and less age-driven.
- **Perforators:** connect superficial → deep; incompetent perforators contribute to recurrent disease.

## Related pages

- [[chronic-venous-disease]] — the aging disease of this tissue (varicose veins / CVI)
- [[arteries]] — the high-pressure conduit counterpart
- [[cardiovascular-aging]] — umbrella phenotype
- [[arterial-stiffening]] — the arterial-side ECM-aging sibling phenotype

## Footnotes

[^bergan]: doi:10.1056/NEJMra055289 · Bergan JJ et al. · *N Engl J Med* 2006;355(5):488–498 · review (landmark) · PMID 16885552 · venous wall structure, valve function, reflux/venous-hypertension mechanism
[^eberhardt]: doi:10.1161/CIRCULATIONAHA.113.006898 · Eberhardt RT, Raffetto JD · *Circulation* 2014;130(4):333–346 · review · PMID 25047584 · venous hemodynamics, calf-pump physiology, CVI mechanism
[^raffetto2021]: doi:10.20517/2574-1209.2021.16 · Raffetto JD, Khalil RA · *Vessel Plus* 2021;5:36 · review (mechanistic) · PMID 34250453 · MMP-1, -2, -3, -7 elevated in VVs (MMP-2 activity specifically increased); MMP/TIMP ECM remodeling of vein wall; collagen+elastin degradation; dilation via BKCa-channel-mediated SMC hyperpolarization
[^raffetto2008]: doi:10.2174/157016108784911957 · Raffetto JD, Khalil RA · *Curr Vasc Pharmacol* 2008;6(3):158–172 · review · PMID 18673156 · MMP-driven venous dilation + valve dysfunction
[^maurins]: doi:10.1016/j.jvs.2008.04.029 · Maurins U et al. (Bonn Vein Study) · *J Vasc Surg* 2008;48(3):680–687 · observational, population-based · enrolled n=3072, analysis n=3016, ages 18–79 · superficial-vein reflux 21.0% (95% CI 19.5–22.5); deep-vein reflux 20.0% (95% CI 18.6–21.5); overall reflux (>500 ms) 35.3%; superficial reflux rises markedly with age, deep shows no clear age trend · PMID 18586443
[^lim2011]: doi:10.1016/j.jvs.2010.09.018 · Lim CS et al. · *J Vasc Surg* 2011;53(3):764–773 · in-vivo (rat IVC) · stretch → HIF upregulation + reduced contraction · PMID 21106323

[^phillips2004]: doi:10.1002/ca.10141 · Phillips MN et al. · *Clin Anat* 2004;17(1):55–60 · anatomical · PMID 14695589 · bicuspid parietal micro-valves with sinus pockets in superficial lower-limb veins, down to ~0.1 mm tributaries
[^banjo1987]: doi:10.1002/ar.1092170413 · Banjo AO · *Anat Rec* 1987;217(4):407–412 · comparative anatomy · PMID 3592268 · valves absent in IVC in all subjects; common iliac 1–7%, external iliac 22–33%, femoral near-SFJ 67–93% — distal-predominant gradient
[^bovill2011]: doi:10.1146/annurev-physiol-012110-142305 · Bovill EG, van der Vliet A · *Annu Rev Physiol* 2011;73:527–545 · review · PMID 21034220 · low-shear valve-sinus pocket is hypoxic; valvular-stasis hypoxia links to thrombosis initiation
[^mackman2012]: doi:10.1172/JCI60229 · Mackman N · *J Clin Invest* 2012;122(7):2331–2336 · review · PMID 22751108 · venous thrombi initiate in valve-sinus pockets (stasis + low O₂)
[^welsh2019]: doi:10.1172/JCI124791 · Welsh JD et al. · *J Clin Invest* 2019;129(12):5489–5500 · in-vivo (mouse + human saphenous vein) · PMID 31710307 · oscillatory/low shear drives a distinct antithrombotic perivalvular endothelial gene program (THBD/thrombomodulin high, EPCR high, TFPI high, vWF low, P-selectin surface-low, ICAM1 low); FOXC2 and PROX1 are specifically expressed in this perivalvular endothelium; conditional Foxc2 deletion in perivalvular endothelium abrogates the antithrombotic phenotype and promotes DVT
[^sabine2012]: doi:10.1016/j.devcel.2011.12.020 · Sabine A et al. · *Dev Cell* 2012;22(2):430–445 · in-vivo (mouse) · PMID 22306086 · keystone lymphatic-valve study: flow-sensing → PROX1 + FOXC2 cooperate to control connexin-37 and calcineurin/NFATc1 in lymphatic-valve formation; the program is shared with venous valves (paper explicitly studies lymphatic vessels; extrapolation to venous valves supported by the overlap in TF expression and the Welsh 2019 in-vivo venous data)
[^munger2013]: doi:10.1016/j.ydbio.2012.10.032 · Munger SJ et al. · *Dev Biol* 2013;373(2):338–348 · in-vivo (mouse KO) · PMID 23142761 · connexin-37 (GJA4)-null mice have profoundly impaired lymphatic valve formation and severely reduced mature venous valves (shared Cx37-dependence across valve beds)
[^bazigou2009]: doi:10.1016/j.devcel.2009.06.017 · Bazigou E et al. · *Dev Cell* 2009;17(2):175–186 · in-vivo (mouse) · PMID 19686679 · integrin-α9 / fibronectin-EIIIA matrix assembly required for valve morphogenesis
[^murtomaki2014]: doi:10.1242/dev.101188 · Murtomaki A et al. · *Development* 2014;141(12):2446–2451 · in-vivo (mouse) · PMID 24917500 · Notch signaling in lymphatic valve formation (shared with cardiac Notch role)
[^lange2006]: doi:10.1016/j.ydbio.2006.01.017 · Lange AW, Yutzey KE · *Dev Biol* 2006;292(2):407–417 · in-vivo (mouse) · PMID 16680826 · NFATc1 in developing heart-valve endocardium (RANKL-responsive) — shared NFATc1/calcineurin axis with venous/lymphatic valves
[^saxon2017]: doi:10.1016/j.ydbio.2017.08.008 · Saxon JG et al. · *Dev Biol* 2017;430(1):113–128 · in-vivo (mouse) · PMID 28790014 · endocardial-lineage BMP2 required for AV cushion maturation (BMP arm of cardiac valve EndMT)
[^raffettophleb2008]: doi:10.1258/phleb.2007.007027 · Raffetto JD, Khalil RA · *Phlebology* 2008;23(2):85–98 · review · PMID 18453484 · distinguishes primary valve incompetence from annular (wall) dilation causing loss of cusp coaptation
[^berganjvs2008]: doi:10.1016/j.jvs.2007.09.028 · Bergan JJ et al. · *J Vasc Surg* 2008;47(1):183–192 · review (animal models) · PMID 18178472 · venous hypertension → leukocyte trapping, inflammation, valve + wall remodeling
[^takase2004]: doi:10.1016/j.jvs.2004.02.044 · Takase S et al. · *J Vasc Surg* 2004;39(5):1060–1066 · in-vivo (animal) · PMID 15192576 · experimental venous hypertension → monocyte/macrophage infiltration of valve leaflets + progressive remodeling
[^chenmmp2017]: doi:10.1016/bs.pmbts.2017.02.003 · Chen Y, Peng W, Raffetto JD, Khalil RA · *Prog Mol Biol Transl Sci* 2017;147:267–299 · review · PMID 28413031 · MMP-mediated ECM degradation in vein wall + valve remodeling
[^lyons2021]: doi:10.1172/jci.insight.140952 · Lyons OTA et al. · *JCI Insight* 2021;6(14):e140952 · human genetics · PMID 34403370 · EPHB4 loss-of-function causes venous valve aplasia/agenesis
[^mellor2007]: doi:10.1161/CIRCULATIONAHA.106.675348 · Mellor RH et al. · *Circulation* 2007;115(14):1912–1920 · human · PMID 17372167 · FOXC2 mutations associated with primary lower-limb venous valve failure (lymphedema-distichiasis)
[^ahalya2025]: doi:10.1007/s00018-025-05854-y · Ahalya S et al. · *Cell Mol Life Sci* 2025;82(1) · review/mechanistic · PMID 41055734 · altered venous flow drives EndMT in varicose veins (venous-side EndMT parallel to cardiac valve EndMT) #gap/needs-replication
[^absi2018]: doi:10.1016/j.athoracsur.2017.11.035 · Absi TS et al. · *Ann Thorac Surg* 2018;105(5):1486–1494 · human molecular · PMID 29248417 · altered ADAMTS5 → versican proteoglycan turnover in Barlow myxomatous mitral valve
[^rajamannan2003]: doi:10.1161/01.CIR.0000070591.21548.69 · Rajamannan NM et al. · *Circulation* 2003;107(17):2181–2184 · human histology · PMID 12719282 · calcified aortic valves express osteoblast markers (Cbfa1/RUNX2, osteopontin) — osteogenic VIC transdifferentiation
[^garg2005]: doi:10.1038/nature03940 · Garg V et al. · *Nature* 2005;437(7056):270–274 · human genetics · PMID 16025100 · NOTCH1 loss-of-function → bicuspid aortic valve + accelerated calcification (Notch represses RUNX2)
[^fukayaval]: doi:10.1161/CIRCULATIONAHA.118.035584 · Fukaya E et al. · *Circulation* 2018;138(25):2869–2880 · GWAS (UK Biobank, 337,536 individuals; 9,577 cases) · PMID 30566020 · PMC6400474 · 30 independent genome-wide significant loci; strongest hit CASZ1 (rs11121615; P=3.71×10⁻⁶⁵); other notable hits: PPP3R1 (calcineurin B regulatory subunit; eQTL for PPP3R1/WDR92/PLEK) and PIEZO1 (rs2911463; P=4.81×10⁻²⁹); FBN2 is an eQTL gene near the PIEZO1/GALNS locus (rs2911463 eQTL associations include GALNS and FBN2) — not itself an independent GWAS locus; height causally associated with varicose veins by MR (IVW OR 1.26; P=2.07×10⁻¹⁶)
[^kuhne2013]: doi:10.1016/j.ijcard.2012.10.044 · Kühne K et al. · *Int J Cardiol* 2013;168(2):1622–1623 · human · PMID 23176764 · FBN1 mutation characteristics predict mitral valve prolapse in Marfan syndrome
[^ho2023]: doi:10.1161/CIRCRESAHA.123.323027 · Ho YC et al. · *Circ Res* 2023;133(5):463–480 · in-vivo (mouse) · PMID 37555328 · PROX1 (venous/lymphatic valve TF) inhibits PDGF-B to prevent myxomatous heart-valve degeneration — direct cross-bed molecular link
